Neena Brizmohun

Neena Brizmohun

Executive Editor

London, UK

Neena has been covering regulatory, business and market access developments that impact pharmaceutical and medical device companies since 1997. She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, pricing and reimbursement, clinical trials, real-world evidence, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.

Latest from Neena Brizmohun

What Pharma Needs To Know About Vietnam’s Drug Registration Reforms

Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

EU Biosimilar Filings, Opinions And Approvals

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Tepezza, Amgen's treatment for moderate to severe thyroid eye disease.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.